EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. Conference

Cahill, Daniel P, George, Asha, Gilbert, Mark R et al. (2013). EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. . MOLECULAR CANCER THERAPEUTICS, 12(11), 10.1158/1535-7163.TARG-13-A110

International Collaboration

cited authors

  • Cahill, Daniel P; George, Asha; Gilbert, Mark R; Chakravarti, Arnab; Stupp, Roger; Hegi, Monika; Brown, Paul; Jaeckle, Kurt A; Corn, Benjamin; Sulman, Erik P; Souhami, Luis; Werner-Wasik, Maria; Anderson, Bethany M; Mehta, Minesh; Aldape, Kenneth D

sustainable development goals

authors

publication date

  • November 1, 2013

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • AMER ASSOC CANCER RESEARCH

volume

  • 12

issue

  • 11